BiotechTube

ARQ-151 cream 0.05%

Phase 2Completed
0 watching 0 views this week⚡ Active
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Atopic Dermatitis (Eczema)

Conditions

Atopic Dermatitis (Eczema)

Trial Timeline

Jun 9, 2025 → Dec 4, 2025

NCT ID
NCT06998056

About ARQ-151 cream 0.05%

ARQ-151 cream 0.05% is a phase 2 stage product being developed by Arcutis Biotherapeutics for Atopic Dermatitis (Eczema). The current trial status is completed. This product is registered under clinical trial identifier NCT06998056. Target conditions include Atopic Dermatitis (Eczema).

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT06998056Phase 2Completed

Competing Products

20 competing products in Atopic Dermatitis (Eczema)

See all competitors
ProductCompanyStageHype Score
LebrikizumabEli LillyPhase 3
77
Baricitinib + Placebo + Topical corticosteroidEli LillyPhase 3
77
LebrikizumabEli LillyApproved
85
LebrikizumabEli LillyPhase 3
77
Lebrikizumab + PlaceboEli LillyPhase 3
77
BioLexa- Cohort 1 + BioLexa- Cohort 2 + Placebo + GentamicinHoth TherapeuticsPhase 1
25
LebrikizumabEli LillyPhase 3
77
ASN008Formation BioPhase 2
44
ENS-002Concerto BiosciencesPhase 1
25
nemolizumab (CIM331)Chugai PharmaceuticalPhase 2
52
YH35324 + Placebo + OmalizumabYuhanPhase 1
33
YH35324 + Placebo + OmalizumabYuhanPhase 1
33
DS-2741a + PlaceboDaiichi SankyoPhase 1
33
SUN13834 + PlaceboDaiichi SankyoPhase 2
52
5 mg ASB17061 + Placebo + 10 mg ASB17061 + 20 mg ASB17061Daiichi SankyoPhase 2
52
Tacrolimus Ointment 0.03% + Tacrolimus Ointment 0.03%Astellas PharmaPhase 2
52
tacrolimus ointmentAstellas PharmaPhase 3
77
tacrolimus 0.1% + fluticasone 0.005 %Astellas PharmaApproved
85
tacrolimus ointment + pimecrolimus creamAstellas PharmaApproved
85
tacrolimus ointment 0.03% + hydrocortisone acetate ointment 1% + hydrocortisone butyrate ointment 0.1% + Meningitec + AC VAXAstellas PharmaPhase 2
52

Other Products from Arcutis Biotherapeutics

ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%Phase 3
72
Roflumilast Cream + Vehicle creamPhase 3
72
Roflumilast Foam 0.3% + Vehicle FoamPhase 3
72
Roflumilast Foam + Vehicle FoamPhase 3
72
Roflumilast Cream 0.05% + Vehicle CreamPhase 3
72